Clinical Report: Assessing the Specific Risk of Respiratory Depression from Opioids

Overview

This retrospective cohort study evaluates the incidence of respiratory depression in patients with non-cancer pain using opioids. It assesses the comparative risk associated with different opioid types and the impact of concomitant medications such as benzodiazepines and gabapentinoids, based on electronic health records from a large tertiary care hospital.

Background

The increasing prescription of opioids for non-cancer pain raises significant safety concerns, particularly regarding respiratory depression, which can lead to fatal outcomes. Understanding the specific risks associated with various opioids and their interactions with other medications is crucial.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The study evaluates the incidence of respiratory depression in opioid users for non-cancer pain.
• It assesses the comparative risk of respiratory depression across different opioid types.
• The study analyzes the effect of daily opioid dose on respiratory depression risk.
• Concomitant use of gabapentinoids and benzodiazepines is expected to influence respiratory depression outcomes.
• Challenges in evaluating respiratory depression include varying definitions and reliance on proxies for opioid exposure.

Clinical Implications

Healthcare professionals should be aware of the differential risks of respiratory depression associated with various opioids and the potential effects of concomitant medications.

Conclusion

The study emphasizes the need for a comprehensive understanding of respiratory depression risks in opioid therapy for non-cancer pain.

Related Resources & Content

1. FDA, FDA, 2025 -- FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks
2. University of Manchester, Research Explorer, 2026 -- Opioid-specific Risk of Respiratory Depression in Non-Cancer Pain: A Retrospective Cohort Study
3. Pain Medicine — Comparative Analysis of Clinical and Psychological Profiles in Patients Undergoing Opioid Use Disorder Treatment Versus Those on Low- and High-Dose Opioids for Pain Management
4. Drugs - Real World Outcomes — An Extensive Observational Analysis of Trends and Risk Factors Associated with Opioid Overdose: Insights from Real-World Data for Improved Opioid Prescribing
5. Pain Medicine — Trends in Opioid Milligram Equivalents and Medical Cannabis Authorization in Chronic Pain Patients: A Retrospective Study
6. Pain Medicine — Association of opioid tapering with pain-related emergency department visits, hospitalizations, and primary care visits: a retrospective cohort study
7. FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks | FDA
8. Opioid-specific Risk of Respiratory Depression in Non-Cancer Pain: A Retrospective Cohort Study - Research Explorer The University of Manchester
9. FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use | FDA